AZ and Amgen jointly develop and sell five inflammation therapies
AstraZeneca PLC, its biologics arm MedImmune LLC, and Amgen Inc. have agreed to jointly develop and commercialize five of Amgen’s clinical-stage monoclonal antibodies: AMG139, AMG157, AMG181, AMG557, and brodalumab (AMG827).
- Large Molecule
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com